Tung-Min Yu1, Ya-Wen Chuang1, Kuo-Ting Sun1, Mei-Ching Yu1, Shiang-Cheng Kung1, Brian K Lee1, Shih-Ting Huang1, Cheng-Hsu Chen1, Cheng-Li Lin1, Chia-Hung Kao2. 1. From the Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine (T.-M.Y., K.-T.S., S.-T.H., C.-H.C., C.-H.K.), Pediatric Dentistry, Dental Department (K.-T.S.), and College of Medicine (C.-L.L.), China Medical University, Taichung; Division of Nephrology (T.-M.Y., Y.-W.C., S.-T.H., C.-H.C.) and Department of Medical Research and Center of Quality Management (C.-H.C.), Taichung Veterans General Hospital, Taiwan; Connie Frank Transplant Center, Division of Nephrology, Department of Medicine (S.-C.K., B.K.L.), UCSF Medical Center, San Francisco, CA; Department of Pediatrics, Division of Nephrology (M.-C.Y.), Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan; Department of Life Science (C.-H.C.), Tunghai University; Management Office for Health Data (C.-L.L.) and Department of Nuclear Medicine and PET Center (C.-H.K.), China Medical University Hospital; and Department of Bioinformatics and Medical Engineering (C.-H.K.), Asia University, Taichung, Taiwan. 2. From the Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine (T.-M.Y., K.-T.S., S.-T.H., C.-H.C., C.-H.K.), Pediatric Dentistry, Dental Department (K.-T.S.), and College of Medicine (C.-L.L.), China Medical University, Taichung; Division of Nephrology (T.-M.Y., Y.-W.C., S.-T.H., C.-H.C.) and Department of Medical Research and Center of Quality Management (C.-H.C.), Taichung Veterans General Hospital, Taiwan; Connie Frank Transplant Center, Division of Nephrology, Department of Medicine (S.-C.K., B.K.L.), UCSF Medical Center, San Francisco, CA; Department of Pediatrics, Division of Nephrology (M.-C.Y.), Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan; Department of Life Science (C.-H.C.), Tunghai University; Management Office for Health Data (C.-L.L.) and Department of Nuclear Medicine and PET Center (C.-H.K.), China Medical University Hospital; and Department of Bioinformatics and Medical Engineering (C.-H.K.), Asia University, Taichung, Taiwan. d10040@mail.cmuh.org.tw.
Abstract
OBJECTIVE: Data on the risk of neurodegenerative diseases, including Alzheimer disease (AD) and Parkinson disease (PD), in patients with polycystic kidney disease (PKD) are lacking. METHODS: A total of 4,229 patients who were aged ≥20 years and had received a diagnosis of PKD were included in the PKD cohort. For each PKD case identified, 1 participant aged ≥20 years without a history of PKD, dementia, or PD was selected from the comparison cohort. For each patient with PKD, the corresponding controls were selected 1:1 on the basis of the nearest propensity score calculated using logistic regression. RESULTS: The incidence density rates of dementia were 4.31 and 2.50 per 1,000 person-years in the PKD and control cohorts, respectively. A 2.04-fold higher risk of dementia was observed in patients with PKD than in controls (adjusted hazard ratio [aHR] 2.04; 95% confidence interval [CI] 1.46-2.85). Regarding the risk of different dementia subtypes, including AD and vascular dementia (VaD), the aHR for AD and presenile dementia was 2.71 (95% CI 1.08-6.75) and that for VaD was 0.90 (95% CI 0.43-1.87) in patients with PKD compared with controls, after adjustment for age, sex, and comorbidities. Compared with controls, the risk of PD increased by 1.78-fold (95% CI 1.14-2.79) in patients with PKD. CONCLUSIONS: In clinical practice, health care professionals should be aware of the risk of neurodegenerative diseases in patients with PKD.
OBJECTIVE: Data on the risk of neurodegenerative diseases, including Alzheimer disease (AD) and Parkinson disease (PD), in patients with polycystic kidney disease (PKD) are lacking. METHODS: A total of 4,229 patients who were aged ≥20 years and had received a diagnosis of PKD were included in the PKD cohort. For each PKD case identified, 1 participant aged ≥20 years without a history of PKD, dementia, or PD was selected from the comparison cohort. For each patient with PKD, the corresponding controls were selected 1:1 on the basis of the nearest propensity score calculated using logistic regression. RESULTS: The incidence density rates of dementia were 4.31 and 2.50 per 1,000 person-years in the PKD and control cohorts, respectively. A 2.04-fold higher risk of dementia was observed in patients with PKD than in controls (adjusted hazard ratio [aHR] 2.04; 95% confidence interval [CI] 1.46-2.85). Regarding the risk of different dementia subtypes, including AD and vascular dementia (VaD), the aHR for AD and presenile dementia was 2.71 (95% CI 1.08-6.75) and that for VaD was 0.90 (95% CI 0.43-1.87) in patients with PKD compared with controls, after adjustment for age, sex, and comorbidities. Compared with controls, the risk of PD increased by 1.78-fold (95% CI 1.14-2.79) in patients with PKD. CONCLUSIONS: In clinical practice, health care professionals should be aware of the risk of neurodegenerative diseases in patients with PKD.